Krka, d. d. Reports Earnings Results for the First Quarter Ended March 31, 2024
May 16, 2024 at 02:15 am EDT
Share
Krka, d. d. reported earnings results for the first quarter ended March 31, 2024. For the first quarter, the company reported sales was EUR 485.47 million compared to EUR 456.41 million a year ago. Revenue was EUR 486.15 million compared to EUR 458.18 million a year ago.
Net income was EUR 98.88 million compared to EUR 89.02 million a year ago. Basic earnings per share from continuing operations was EUR 3.21 compared to EUR 2.87 a year ago. Diluted earnings per share from continuing operations was EUR 3.21 compared to EUR 2.87 a year ago.
Krka dd Novo Mesto is a Slovenia-based company engaged in the production of pharmaceutical preparations. The Company operates through four segments: Prescription Pharmaceuticals that includes medicines for the treatment of cardiovascular diseases, alimentary tract and metabolism and drugs for diseases of the central nervous system, among others; Non-prescription Products, providing vitamins and minerals, cough and cold products, analgesics, sore throat products, among others; Animal Health Products, which offers general anti-infectives and antiparasitics for animals; Health Resort and Tourist Services consisting of Spa resorts in Smarjeske Toplice, Dolenjske Toplice, Strunjan, Novo Mesto and Otocec. Krka dd Novo Mesto is a controlling company of the Krka Group that includes two subsidiaries in Slovenia, Terme Krka doo and Farma GRS doo, and over 20 subsidiaries abroad in such countries as Croatia, Germany, Sweden, Poland, Spain, United States, Ireland, among others.
KRKA, D. D. 
